Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Follow-On Growth Hormone Has Precedent, Sandoz Says In Response To Pfizer

Executive Summary

FDA's approval of Novo Nordisk's GlucaGen demonstrates that the agency has the legal authority to approve a follow-on version of human growth hormone, Sandoz maintains
Advertisement

Related Content

Follow-On And Wait: FDA Defers Action On Sandoz’s Human Growth Hormone
Follow-On And Wait: FDA Defers Action On Sandoz’s Human Growth Hormone
FDA Follow-On Biologics Public Meeting Slated For Early ’05
FDA Follow-On Biologics Public Meeting Slated For Early ’05
Follow-On Biologics Will Rely On “Case-By-Case” Approach – Rep. Waxman
Follow-On Biologics Guidance Will Follow Public Workshop, FDA Tells Senate
Sandoz Omnitrope NDA Is Test For Follow-On Biologics; Pfizer Says No
Generic Biologics: 505(b)(2) Route Still Open, But Scientific Issues Unresolved
Novo GlucaGen Launch For Hypoglycemia Awaits Co-Marketing Agreement
Novo GlucaGen Launch For Hypoglycemia Awaits Co-Marketing Agreement

Topics

Advertisement
UsernamePublicRestriction

Register

PS044350

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel